ZYDUSLIFE

Zydus Lifesciences – Zycubo Breakthrough - Zycubo gets FDA nod for Menkes disease — first & only approved therapy. - Extends median survival from <18 months to ~177 months when treated early. - Peak sales potential: ~US$50 mn; price est. at ~US$600k per patient per year. - Ethical questions aside, a meaningful medical and commercial milestone.